• Smart cancer nanomedicine

Treffer: Smart cancer nanomedicine

Title:
Smart cancer nanomedicine
Authors:
van der Meel, Roy, Sulheim, Einar, Shi, Y., Kiessling, F., Mulder, Willem, Lammers, Twan
Source:
van der Meel, R, Sulheim, E, Shi, Y, Kiessling, F, Mulder, W & Lammers, T 2019, 'Smart cancer nanomedicine', Nature Nanotechnology, vol. 14, no. 11, pp. 1007–1017. https://doi.org/10.1038/s41565-019-0567-y
Publication Year:
2019
Subject Terms:
Animals, Antineoplastic Agents/administration & dosage, Biomarkers, Tumor/analysis, Drug Carriers/chemistry, Drug Delivery Systems/methods, Drug Development/methods, Humans, Immunotherapy/methods, Nanomedicine/methods, Nanoparticles/chemistry, Neoplasms/diagnosis, Translational Medical Research/methods, /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, name=SDG 3 - Good Health and Well-being
Document Type:
Fachzeitschrift article in journal/newspaper
Language:
English
ISSN:
1748-3387
1748-3395
Relation:
info:eu-repo/semantics/altIdentifier/pmid/31695150; info:eu-repo/semantics/altIdentifier/wos/000495608700007; info:eu-repo/semantics/altIdentifier/pissn/1748-3387; info:eu-repo/semantics/altIdentifier/eissn/1748-3395
DOI:
10.1038/s41565-019-0567-y
Availability:
https://research.tue.nl/en/publications/d0f6b3b6-6283-4ebf-b712-d252c6e8231d
https://doi.org/10.1038/s41565-019-0567-y
https://www.scopus.com/pages/publications/85074626665
Rights:
info:eu-repo/semantics/openAccess
Accession Number:
edsbas.2BF89339
Database:
BASE

Weitere Informationen

Nanomedicines are extensively employed in cancer therapy. We here propose four strategic directions to improve nanomedicine translation and exploitation. (1) Patient stratification has become common practice in oncology drug development. Accordingly, probes and protocols for patient stratification are urgently needed in cancer nanomedicine, to identify individuals suitable for inclusion in clinical trials. (2) Rational drug selection is crucial for clinical and commercial success. Opportunistic choices based on drug availability should be replaced by investments in modular (pro)drug and nanocarrier design. (3) Combination therapies are the mainstay of clinical cancer care. Nanomedicines synergize with pharmacological and physical co-treatments, and should be increasingly integrated in multimodal combination therapy regimens. (4) Immunotherapy is revolutionizing the treatment of cancer. Nanomedicines can modulate the behaviour of myeloid and lymphoid cells, thereby empowering anticancer immunity and immunotherapy efficacy. Alone and especially together, these four directions will fuel and foster the development of successful cancer nanomedicine therapies.